Table 2.
Patient characteristics in 40 studies assessing the prognostic role of T1 substaging in patients with bladder urothelial carcinoma
| Author | Age, year (range) | Independent correlation with oncologic outcomes | Follow-up duration |
|---|---|---|---|
| Hasui [23] | Mean: 68 (37–95) | S | N/A |
| Holmäng [24] | Mean: 73.1 (48–97) | S (for DP and CSS) | ≥ 5 years |
| Smits [40] | N/A | S (for PFS) | Minimal follow-up: 3 years |
| Cheng [22] | Mean: 71 (47–94) | S | Mean: 5.2 years (range, 1 day–10.4) |
| Kondylis [26] | N/A | NS | Median 71 months (range, 4–147) |
| Shariat [39] | Median: 67 (30–86) | NS | Median: 79 months |
| Bernardini [17] | Mean: 68.9 (42–90) | S | Mean: 64.9 months (range, 5–288) |
| Sozen [42] | Median: 62 (33–84) | S | Mean: 68 months (range, 24–120) |
| Orsola [32] | Mean: 66.4(30.3–86.8) | S (in T1b/c vs T1a substaging for RFS and PFS) | Mean: 53 months |
| van der Aa [45] | Mean: 68 (47–90) | S | Median: 55 months (range, 9–228) |
| Chaimuangraj [20] | Mean: 60 (43–83) | S | N/A |
| Andius [13] | Median: 74 (48–98) | NS | Median: 15 years for alive cases |
| Mhawech-Fauceglia [29] | Mean: 70 | S (for DP) | Median: 12 months |
| Queipo-Zaragoza [37] | Mean: 68.1 | S | Mean: 57.8 months (range, 13–24) |
| Soukup [16] | Mean: 68.43 (38–87) | S (for PFS) | Mean: 23.31 months |
| Orsola [14] | Mean: 69 | S (for DP) | Median: 20.3 months |
| Bertz [18] | Median: 71.7 (38–87 years). | S (in Infiltration depth: ≤ 1 HPF vs > 1 HPF for RFS and PFS) | Mean: 49 months (range, 5–172) |
| Palou [34] | Mean: 64.9 (25–81) | NS | Median: 8.7 years |
| Lee [27] | Mean: 63.5 years (27–93) | S (for DP and CSM) | Mean: 43.5 months (range, 12–146) |
| Chang [21] | Mean: 71 (23–92) | S (MM invasion: S for DP, CSM, and OM) (depth of high-grade tumor: S for DR, DP, CSM, OM) |
Mean: 88 months (range, 1–240) for patients who were alive Mean: 39 months (range, 1–193) for patients who died |
| van Rhijn [46] | Mean: 68.8 | S (in T1 m/T1e for DP) | Median: 6.5 years |
| Brimo [19] | Mean: 71 | S | Mean: 29 months |
| Olsson [31] | Median: 74 | S (in T1b/c vs T1a substaging for DP in patients older than 73 years) | Median: 60 months |
| Nishiyama [30] | Mean: 68.5 | S (for DR) | Mean: 74.0 months |
| Rouprêt [38] | Median: 70 | S | Mean: 44 months (range, 6–161) |
| Soukup [41] | Median: 68.83 (17.55–86.94) | S (for PFS, CSS, OS) | Median: 3.13 years (0.1–10.5) |
| Hu [25] | Mean: 70 years (56–94) | S (in aggregate length of invasion; > 0.5 cm) | N/A |
| D. E. Marco [44] | Mean: 69.9 | NS | Median: 9.5 years |
| Lim [28] | Mean: 68.9 (20–93) | S (for PFS) | Mean: 73.3 months (range, 3.9–187.9) |
| Orsola [15] | Median: 71 | S (for DP) | Median: 71 months (range: 5–107) |
| Patschan [36] | Median: 74 | NS | (3 years follow-up in analysis) |
| Patriarca [35] | Mean: 71.3 (64–79) | S (in ROL1 VS ROL 2 substaging for DP) | Mean: 46 months |
| Colombo [8] | Mean: 70 (64–77) | S (for DP in ROL2 vs ROL1 substaging) | Median: of 60 months |
| Fransen van de Putte [9] | Median: 71 | S (for PFS and CSS in T1e vs T1 m substaging) | Median: 5.9 years |
| Otto [33] | Median: 72 | NS | Median: 42 months |
| Turan [43] | Mean: 67.9 | S (in T1a/b substaging for DR) | Mean: 54 months |
N/A not available, S significant, NS non-significant, MM muscularis mucosa PFS progression-free survival, CSM cancer-specific mortality, CSS cancer-specific survival, OS overall survival, OM overall mortality, DR disease recurrence, DP disease progression, RFS recurrence-free survival, HPF high power field
†S statistical significance p value < 0.05